Toward a Multidimensional Formulation of Alzheimer's Disease Pathogenesis and Pathophysiology

Article

Rodrigo O. Kuljis discusses the challenges to our understanding of neurodegenerative disorders and to the development of effective treatments and prevention presented because we lack a “satisfactory, unanimously agreed and unifying conceptual scheme” for them.

Presenter Rodrigo O. Kuljis discusses the challenges to our understanding of neurodegenerative disorders and to the development of effective treatments and prevention presented because we lack a “satisfactory, unanimously agreed and unifying conceptual scheme” for them. Dr. Kuljis’ proposes that resolving this will require researchers to address “in an integrated fashion the multiple dimensions and scales of organization of the central nervous system, that transcend the conventional boundaries of biochemistry/molecular biology, systems neuroscience, and nosology—among others—as well as going beyond the timescales usually considered in this approach.” His poster presentation offered “a more integrated conceptual scheme to tackle the complexity of neurodegenerative disorders” and offered “considerable advantages over the present, admittedly fruitful, but not yet sufficiently successful and increasingly “atomizing” analytic approach to Alzheimer’s disease and most other degenerative conditions that cause dementia.”

MP3 DOWNLOAD: RODRIGO_KULJIS.mp3

(Right click to download podcasts)

Related Videos
Daniel Karlin, MD: Prevalence of Undiagnosed Generalized Anxiety Disorder
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Paul Appelbaum, MD: What to Warn Patients When Prescribing Psychedelics in the Future
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Ryan McLaughlin, PhD: Challenges Studying Cannabis to Treat Psychiatric Illness
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Charles R. Marmar, MD: Blood Biomarkers for PTSD
© 2024 MJH Life Sciences

All rights reserved.